Arcus Biosciences Inc (RCUS)
NYSE:RCUS
Want to see RCUS full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.89Last Year’s EPS
0Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong clinical differentiation and durable efficacy for cascadifan (notably improved ORR and substantially longer PFS versus a competitor), accelerating enrollment in the registrational PEEK-1 study, a solid cash position with runway into 2028, and a rapidly advancing I&I small-molecule pipeline (AB-102 and others). Offsetting these positives were a late-stage program discontinuation (STAR-121), competitor frontline/triplet failures that create class-level caution, and high near-term R&D spend in Q1 (with nonrecurring costs and a ~10% headcount reduction). On balance, the company presented multiple high-value catalysts, clear prioritization of cascadifan, and a strong balance sheet to execute—outweighing the program setbacks and near-term expense noise.Company Guidance
Strong cash position and runway
Cash and investments of $876 million at quarter end with runway into at least 2028; expected cash of approximately $600 million at year-end 2026.
Q1 GAAP revenue and 2026 guidance
Reported GAAP revenue of $17 million in Q1; company continues to expect full-year 2026 GAAP revenue of $50 million to $65 million.
Cascadifan late-line monotherapy efficacy — ORR gains
100 mg QD cohort confirmed ORR increased from 35% to 45% (a +10 percentage-point increase, ~+28.6% relative); pooled confirmed ORR improved from 31% to 35% (+4 pp, ~+12.9% relative).
Cascadifan durable PFS advantage
100 mg cohort median PFS of 15.1 months (median follow-up 17.9 months) and pooled median PFS of 12.2 months versus 5.6 months reported for belzutafan in the same setting — roughly 2–3x longer PFS (e.g., 15.1 vs 5.6 months is ~170% longer / ~2.7x).
PEEK-1 enrollment accelerating and timeline
Registrational Phase 3 PEEK-1 (second-line cascadifan + cabozantinib vs cabo) is enrolling rapidly and on track to complete enrollment by year-end 2026; trial targets ~20,000 patients in major markets for the IO-experienced setting and a commercial opportunity > $2 billion in that setting.
Frontline combination early signals
ARC-20 cascadifan + zimberelimab first-line cohort showed a low primary progressive disease rate of 7% (2/30), comparable to TKI-containing regimens and supportive of a TKI-sparing frontline approach.
Large commercial opportunity for cascadifan
Management estimates peak sales potential of $5 billion to $10 billion globally; > $2 billion opportunity in IO-experienced second-line and > $4 billion potential in frontline settings.
Progress in immunology & inflammation pipeline
AB-102 (MRGPRX2 antagonist) expected to enter clinic in Q3 2026 with PK data shortly after and potential proof-of-concept in early 2027; oral small-molecule TNF inhibitor and CCR6 antagonist candidates expected to enter clinic in 2027.
PRISM-1 fully enrolled with readout timeline
PRISM-1 (quemliclustat + gemcitabine/nab-paclitaxel in frontline pancreatic cancer) completed enrollment in Sept 2025 with results expected in 2027.
Portfolio re-focus and expected reduced spend
Company expects significantly reduced R&D spend in 2026 and 2027 (greater focus on cascadifan), decreased headcount by ~10%, and plans for >80% of 2027 portfolio spend directed to cascadifan.
RCUS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RCUS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $20.27 | $19.54 | -3.60% |
Oct 28, 2025 | $19.88 | $20.29 | +2.06% |
Aug 06, 2025 | $9.49 | $9.28 | -2.21% |
May 06, 2025 | $8.12 | $8.01 | -1.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Arcus Biosciences Inc (RCUS) report earnings?
Arcus Biosciences Inc (RCUS) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Arcus Biosciences Inc (RCUS) earnings time?
Arcus Biosciences Inc (RCUS) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RCUS EPS forecast?
RCUS EPS forecast for the fiscal quarter 2026 (Q2) is -0.89.